Yung-Jue Bang
New Generation University College
667 Papers
5.5K Citations
Yung-Jue Bang is an academic researcher from New Generation University College. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 94, co-authored 664 publications. Previous affiliations of Yung-Jue Bang include Seoul National University Hospital & Seoul National University.
Chat about Author
Papers
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
Kyung-Hun Lee,Hye Sook Min,Sae-Won Han,Do-Youn Oh,Do-Youn Oh,Se-Hoon Lee,Se-Hoon Lee,Dong Wan Kim,Dong Wan Kim,Seock-Ah Im,Seock-Ah Im,Doo Hyun Chung,Doo Hyun Chung,Young Tae Kim,Tae-You Kim,Tae-You Kim,Dae Seog Heo,Dae Seog Heo,Yung-Jue Bang,Yung-Jue Bang,Sook Whan Sung,Joohyun Kim +21 more
TL;DR: ERCC1 expression was identified as a positive prognostic marker in resected NSCLC, and EGFR mutations were more frequently found in ERCC1-negative tumors.
81
Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma
TL;DR: Adjuvant radiotherapy after chemotherapy did not improve outcome in stage I/II nasal NTCL, and the International Prognostic Index was a significant prognostic factor of complete remission rate, and stage was also significant for disease-free survival.
80
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
Bhumsuk Keam,Sung Bae Kim,Seong Hoon Shin,Byoung Chul Cho,Keun Wook Lee,Min Kyoung Kim,Hwan Jung Yun,Se-Hoon Lee,Dok Hyun Yoon,Yung-Jue Bang +9 more
TL;DR: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC).
79
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
Bhumsuk Keam,Seock-Ah Im,Seock-Ah Im,Sae-Won Han,Hye Seon Ham,Min A Kim,Min A Kim,Do-Youn Oh,Do-Youn Oh,Se-Hoon Lee,Se-Hoon Lee,Jee Hyun Kim,Jee Hyun Kim,Dong Wan Kim,Dong Wan Kim,Tae-You Kim,Tae-You Kim,Dae Seog Heo,Dae Seog Heo,Woo Ho Kim,Woo Ho Kim,Yung-Jue Bang,Yung-Jue Bang +22 more
TL;DR: Modified FOL FOX-6 chemotherapy appears to be active and well tolerated as first line chemotherapy in AGC patients and might be a candidate to select patients who are likely to benefit from 5-FU based modified FOLFOX-6 in future large scale trial.
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer
TL;DR: The results suggest that expression of COX-2 in ovarian cancers is specific to histologic type of tumor and is associated with poor clinicopathologic prognostic factors.
77